EUCTR2015-000307-10-NOActive, not recruitingNot Applicable
AZD9291, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies. - TREM
Oslo university hospital0 sites150 target enrollmentStarted: March 23, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Active, not recruiting
Not Applicable
ew targeted therapy in relapsed EGFR-mutated lung cancer previously treated with EGFR-inhibitorsocally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapyEUCTR2015-000307-10-FIOslo university hospital150
Active, not recruiting
Phase 1
ew targeted therapy in relapsed EGFR-mutated lung cancer previously treated with EGFR-inhibitorsocally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapyEUCTR2015-000307-10-SEOslo university hospital150
Active, not recruiting
Phase 1
ew targeted therapy in relapsed EGFR-mutated lung cancer previously treated with EGFR-inhibitorsocally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapyMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000307-10-DKOslo university hospital200
Active, not recruiting
Phase 2
AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational StudiesTargeted TherapyLung CancerNCT02504346Oslo University Hospital200
Active, not recruiting
Phase 1
Optimalt tidspunkt for at skifte behandling fra Tarceva til Tagrisso.ung CancerMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-005637-47-DKDepartment of Oncology, Aarhus University Hospital50